Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

被引：5
|
作者：
Kreuziger, Lisa Baumann [1 ]
Streiff, Michael [2 ]
机构：
[1] Med Coll Wisconsin, BloodCtr Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2016年
关键词：
RECURRENT VENOUS THROMBOEMBOLISM; CLINICAL-PRACTICE GUIDELINES; ED AMERICAN-COLLEGE; THERAPEUTIC ENOXAPARIN; ANTITHROMBOTIC THERAPY; RENAL-INSUFFICIENCY; THROMBOSIS; PREVENTION; ANTICOAGULATION;
D O I：
10.1182/asheducation-2016.1.206
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL, with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?
引用
收藏
页码：206 / 207
页数：2
相关论文
共 50 条
  • [1] Stability of Plasma Anti-Xa Activity in Low-Molecular-Weight Heparin Monitoring
    Rojnuckarin, Ponlapat
    Akkawat, Benjaporn
    Juntiang, Jumlong
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2010, 16 (03) : 313 - 317
  • [2] Anti-Xa Monitoring of Low-Molecular-Weight Heparin during Pregnancy: A Systematic Review
    Kjaergaard, Amalie Baun
    Fuglsang, Jens
    Hvas, Anne-Mette
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2021, 47 (07): : 824 - 842
  • [3] Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
    Xu, Lengnan
    Sun, Ying
    Wang, Songlan
    Li, Chuanbao
    Mao, Yonghui
    [J]. ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2251 - 2256
  • [4] Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
    Lengnan Xu
    Ying Sun
    Songlan Wang
    Chuanbao Li
    Yonghui Mao
    [J]. Annals of Hematology, 2023, 102 : 2251 - 2256
  • [5] THE ANTI-XA ACTIVITY OF DESMIN 370 IS ATTRIBUTABLE TO LOW-MOLECULAR-WEIGHT HEPARIN
    BRIEGER, D
    DAWES, J
    [J]. THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1351 - 1351
  • [6] Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency
    van den Broek, M. P. H.
    Verschueren, Marjon V.
    Knibbe, C. A. J.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1155 - 1163
  • [7] Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
    Trunfio, Mattia
    Salvador, Elena
    Cabodi, Daniela
    Marinaro, Letizia
    Alcantarini, Chiara
    Gaviraghi, Alberto
    Trentalange, Alice
    Lipani, Filippo
    Sciascia, Savino
    Roccatello, Dario
    Bonora, Stefano
    Di Perri, Giovanni
    Calcagno, Andrea
    [J]. THROMBOSIS RESEARCH, 2020, 196 : 432 - 434
  • [8] Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins
    Hesham S. Al-Sallami
    Michael A. Barras
    Bruce Green
    Stephen B. Duffull
    [J]. Clinical Pharmacokinetics, 2010, 49 : 567 - 571
  • [9] Routine Plasma Anti-Xa Monitoring is Required for Low-Molecular-Weight Heparins
    Al-Sallami, Hesham S.
    Barras, Michael A.
    Green, Bruce
    Duffull, Stephen B.
    [J]. CLINICAL PHARMACOKINETICS, 2010, 49 (09) : 567 - 571
  • [10] Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease
    Gallieni, Maurizio
    Martini, Alma
    Granata, Antonio
    Fusaro, Maria
    [J]. CLINICAL PHARMACOKINETICS, 2010, 49 (11) : 773 - 774
12345